2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.
Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.
Focal therapy is a new concept that destroys small tumors while leaving the prostate intact and sparing most of the surrounding healthy tissue. It is intended to reduce the morbidity of treatment.
The efficacy of these treatments need to be proven over time, Koo says, and data will show in a number of years if cancer was missed in the areas left untreated.
Related Content: